Skip to content
ES
MARKETS / NASDAQ / YDES
NASDAQ · SERVICES-MEDICAL LABORATORIES · SMALL CAP

YD Bio Ltd. YDES

3 fiscal years on record · USD · FY2025 reported · SEC filings only
$596,817
▲ 16.9% YoY
$-8.3M
$-8.0M
In brief

What this company does

We are a publicly listed biotechnology company focused on regulated diagnostics, life science clinical services, and healthcare product commercialization. Our operations include DNA methylation-based oncology testing programs in the United States conducted under a LDT framework in collaboration with CLIA-certified and CAP-accredited laboratory partners. In addition to our diagnostics activities, we provide regulated life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology companies, including procurement, logistics coordination, and compliance-focused support for clinical development programs. We also maintain ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia under applicable regulatory and market requirements. We currently market our cancer detection test products exclusively to licensed HCPs, who order testing through EG BioMed’s CLIA-certified and CAP-accredited laboratory.

Written from the business description in YD Bio Limited's annual report to the U.S. Securities and Exchange Commission, filed 30 April 2026. Every sentence was checked against that document before publication.

Growth
USD 596,817.00
Revenue, FY2025 · full 3-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.6 · Net income -8.3
-4M-8M202320242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−1393 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -883.3% · Net -1392.6%
-500%-1000%202320242025
ROE
FY2025 · ROE -445.1%
20%40%-200%-400%202320242025
Gross margin28.1%
Operating margin-883.3%
Net margin-1392.6%
Return on assets-80.5%
EBITDAUSD -5.3M

Each USD of equity lost 445 cents this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -8.0
-4M-8M202320242025
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 13.8M
EquityUSD -2.9M
CashUSD 6.0M
Gross debtUSD 6,764.00
Net debtUSD -6.0M
Current ratio5.88×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 3-year record
3 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 202520242023
Revenue $B0.00.00.0
Operating income $B−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0
Income tax $B−0.00.00.0
Net income $B−0.0−0.00.0
Free cash flow $B−0.0−0.0−0.0
EPS, diluted $−0.12−0.020.00
Dividend / sh $···
Payout %···
ROE %−445.1−42.759.0
Shares out B0.070.06·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 12 reconciliationsAUDITED

Reconciled in 3 of 19 fiscal years. 83 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Medical Laboratories
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2023

Share this section

Download image